2.61
price up icon0.77%   0.02
after-market Dopo l'orario di chiusura: 2.66 0.05 +1.92%
loading
Precedente Chiudi:
$2.59
Aprire:
$2.61
Volume 24 ore:
261.84K
Relative Volume:
1.46
Capitalizzazione di mercato:
$53.64M
Reddito:
-
Utile/perdita netta:
$-69.17M
Rapporto P/E:
-0.4394
EPS:
-5.94
Flusso di cassa netto:
$-33.93M
1 W Prestazione:
+11.54%
1M Prestazione:
+45.81%
6M Prestazione:
-10.31%
1 anno Prestazione:
+93.33%
Intervallo 1D:
Value
$2.56
$2.74
Intervallo di 1 settimana:
Value
$2.245
$2.74
Portata 52W:
Value
$1.04
$5.24

Protara Therapeutics Inc Stock (TARA) Company Profile

Name
Nome
Protara Therapeutics Inc
Name
Telefono
646-844-0337
Name
Indirizzo
345 PARK AVENUE SOUTH, NEW YORK, NY
Name
Dipendente
27
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-04
Name
Ultimi documenti SEC
Name
TARA's Discussions on Twitter

Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2021-06-04 Iniziato H.C. Wainwright Buy
2021-02-17 Iniziato Oppenheimer Outperform
2020-10-19 Iniziato Cowen Outperform
2020-07-29 Iniziato Guggenheim Buy

Protara Therapeutics Inc Borsa (TARA) Ultime notizie

pulisher
Oct 22, 2024

FDA fast tracks Protara's choline chloride therapy By Investing.com - Investing.com Australia

Oct 22, 2024
pulisher
Oct 21, 2024

FDA fast tracks Protara's choline chloride therapy - Investing.com

Oct 21, 2024
pulisher
Oct 21, 2024

Protara Therapeutics Granted FDA Fast Track Designation for - GlobeNewswire

Oct 21, 2024
pulisher
Oct 21, 2024

Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support - Yahoo Finance

Oct 21, 2024
pulisher
Oct 19, 2024

Protara Therapeutics (FRA:1KPA) Cyclically Adjusted FCF per Share : €0.00 (As of Jun. 2024) - GuruFocus.com

Oct 19, 2024
pulisher
Sep 12, 2024

Opaleye Management Inc. Reduces Stake in Protara Therapeutics Inc. - GuruFocus.com

Sep 12, 2024
pulisher
Sep 11, 2024

Investing in Protara Therapeutics Inc (TARA) Is Getting More Attractive - Knox Daily

Sep 11, 2024
pulisher
Sep 10, 2024

Opaleye Management Inc. sells shares in Protara Therapeutics - Investing.com India

Sep 10, 2024
pulisher
Sep 10, 2024

Opaleye Management Inc. sells shares in Protara Therapeutics By Investing.com - Investing.com Canada

Sep 10, 2024
pulisher
Sep 09, 2024

Protara reveals high choline deficiency in PS patients - Investing.com India

Sep 09, 2024
pulisher
Sep 09, 2024

Protara Therapeutics Announces Results from THRIVE-1, a - GlobeNewswire

Sep 09, 2024
pulisher
Sep 09, 2024

Protara reveals high choline deficiency in PS patients By Investing.com - Investing.com Canada

Sep 09, 2024
pulisher
Sep 09, 2024

Protara Therapeutics Announces Completion of First Cohort - GlobeNewswire

Sep 09, 2024
pulisher
Sep 09, 2024

Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations - StockTitan

Sep 09, 2024
pulisher
Sep 09, 2024

Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support - StockTitan

Sep 09, 2024
pulisher
Sep 03, 2024

Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire

Sep 03, 2024
pulisher
Sep 02, 2024

Analyzing Genasys Inc (GNSS) After Recent Trading Activity - Knox Daily

Sep 02, 2024
pulisher
Sep 02, 2024

Check Out Protara Therapeutics Inc (TARA)’s Trade Data Rather Than the Analysts’ Views - SETE News

Sep 02, 2024
pulisher
Sep 02, 2024

Investor’s Delight: Protara Therapeutics Inc (TARA) Closes Weak at 2.00, Down -0.99 - The Dwinnex

Sep 02, 2024
pulisher
Sep 02, 2024

A year in review: Protara Therapeutics Inc (TARA)’s performance in the last year - US Post News

Sep 02, 2024
pulisher
Sep 02, 2024

Bowhead Specialty Holdings Inc. (BOW) receives an Outperform rating from RBC Capital Mkts - Knox Daily

Sep 02, 2024
pulisher
Aug 21, 2024

Lymphatic Malformations Market to Observe Impressive Growth During the Forecast Period | Vanthera, Protara, Cerecor, Bridge Bio, Palvella, Zynerba - Barchart

Aug 21, 2024
pulisher
Aug 21, 2024

Monitoring Protara Therapeutics Inc (TARA) after recent insider movements - Knox Daily

Aug 21, 2024
pulisher
Aug 20, 2024

Protara Therapeutics (NASDAQ:TARA) Stock, Analyst Ratings, Price Targets, Forecasts - Benzinga

Aug 20, 2024
pulisher
Aug 20, 2024

TARA (Protara Therapeutics) Price-to-Free-Cash-Flow : N/A (As of Aug. 20, 2024) - GuruFocus.com

Aug 20, 2024
pulisher
Aug 19, 2024

Protara Therapeutics (FRA:1KPA) 5-Day RSI : 59.63 (As of Aug. 19, 2024) - GuruFocus.com

Aug 19, 2024
pulisher
Aug 19, 2024

TARA (Protara Therapeutics) Debt-to-Revenue : N/A (As of Jun. 2024) - GuruFocus.com

Aug 19, 2024
pulisher
Aug 19, 2024

TARA (Protara Therapeutics) EV-to-Revenue : (As of Aug. 19, 2024) - GuruFocus.com

Aug 19, 2024
pulisher
Aug 18, 2024

TARA (Protara Therapeutics) Peter Lynch Fair Value : N/A (As of Aug. 18, 2024) - GuruFocus.com

Aug 18, 2024
pulisher
Aug 17, 2024

Protara Therapeutics (FRA:1KPA) GF Value Rank : 0 (As of Aug. 17, 2024) - GuruFocus.com

Aug 17, 2024
pulisher
Aug 17, 2024

Protara Therapeutics (FRA:1KPA) Price-to-Operating-Cash-Flo - GuruFocus.com

Aug 17, 2024
pulisher
Aug 17, 2024

Protara Therapeutics (FRA:1KPA) Volatility : 109.18% (As of Aug. 17, 2024) - GuruFocus.com

Aug 17, 2024
pulisher
Aug 16, 2024

Protara Therapeutics (STU:1KPA) 5-Year Dividend Growth Rate : 0.00% (As of Jun. 2024) - GuruFocus.com

Aug 16, 2024
pulisher
Aug 16, 2024

Protara Therapeutics (STU:1KPA) Forward Dividend Yield % : 0.00% (As of Aug. 16, 2024) - GuruFocus.com

Aug 16, 2024
pulisher
Aug 16, 2024

Protara Therapeutics (STU:1KPA) 3-Year EBITDA Growth Rate : 6.50% (As of Jun. 2024) - GuruFocus.com

Aug 16, 2024
pulisher
Aug 13, 2024

Protara Therapeutics (NASDAQ:TARA) Given New $25.00 Price Target at Oppenheimer - Defense World

Aug 13, 2024
pulisher
Aug 09, 2024

Q3 2024 EPS Estimates for Protara Therapeutics, Inc. Increased by Analyst (NASDAQ:TARA) - Defense World

Aug 09, 2024
pulisher
Aug 09, 2024

Protara Therapeutics (NASDAQ:TARA) & Elevation Oncology (NASDAQ:ELEV) Head to Head Review - Defense World

Aug 09, 2024
pulisher
Aug 08, 2024

HC Wainwright Reaffirms Buy Rating for Protara Therapeutics (NASDAQ:TARA) - Defense World

Aug 08, 2024
pulisher
Aug 08, 2024

Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Invest In Growth? - Simply Wall St

Aug 08, 2024
pulisher
Aug 07, 2024

Protara Therapeutics price target lowered to $20 from $22 at Guggenheim - TipRanks

Aug 07, 2024
pulisher
Aug 07, 2024

Protara Therapeutics: Q2 Earnings Snapshot - San Antonio Express-News

Aug 07, 2024
pulisher
Aug 07, 2024

Head to Head Review: Protara Therapeutics (NASDAQ:TARA) and Gilead Sciences (NASDAQ:GILD) - Defense World

Aug 07, 2024
pulisher
Aug 06, 2024

TARA Stock Earnings: Protara Therapeutics Beats EPS for Q2 2024 - MSN

Aug 06, 2024
pulisher
Aug 06, 2024

Protara Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update - GlobeNewswire

Aug 06, 2024
pulisher
Jul 27, 2024

Head to Head Survey: Protara Therapeutics (NASDAQ:TARA) vs. LENZ Therapeutics (NASDAQ:LENZ) - Defense World

Jul 27, 2024
pulisher
Jul 21, 2024

Oppenheimer & Co. Inc. Takes $40,000 Position in Protara Therapeutics, Inc. (NASDAQ:TARA) - American Banking and Market News

Jul 21, 2024
pulisher
Jul 19, 2024

Protara Therapeutics, Inc. (NASDAQ:TARA) Major Shareholder Opaleye Management Inc. Sells 11,396 Shares of Stock - Defense World

Jul 19, 2024
pulisher
Jul 18, 2024

Opaleye Management sells shares in Protara Therapeutics worth over $27k - Investing.com India

Jul 18, 2024
pulisher
Jul 17, 2024

Protara Therapeutics Inc (TARA) Becoming More Attractive for Investors - Knox Daily

Jul 17, 2024
pulisher
Jul 12, 2024

Protara Therapeutics, Inc. (NASDAQ:TARA) Major Shareholder Opaleye Management Inc. Sells 8,497 Shares of Stock - Defense World

Jul 12, 2024

Protara Therapeutics Inc Azioni (TARA) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Capitalizzazione:     |  Volume (24 ore):